ACORDA THERAPEUTICS INC (ACOR) Stock Price, Quote, News and Overview
NASDAQ:ACOR - Nasdaq - US00484M7002 - Common Stock - Currency: USD
ACOR Quote, Performance and Key Statistics
0.661
-0.22 (-24.86%)
The current stock price of ACOR is 0.661 USD. In the past month the price decreased by -94.67%. In the past year, price decreased by -93.76%.
ACOR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ACOR
Company Profile
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Pearl River, New York and currently employs 111 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Company Info
ACORDA THERAPEUTICS INC
Two Blue Hill Plaza
Pearl River NEW YORK 10502 US
CEO: Ron Cohen
Employees: 111
Company Website: https://www.acorda.com/
Phone: 19143474300
ACORDA THERAPEUTICS INC / ACOR FAQ
What is the stock price of ACORDA THERAPEUTICS INC today?
The current stock price of ACOR is 0.661 USD. The price decreased by -24.86% in the last trading session.
What is the ticker symbol for ACORDA THERAPEUTICS INC stock?
The exchange symbol of ACORDA THERAPEUTICS INC is ACOR and it is listed on the Nasdaq exchange.
On which exchange is ACOR stock listed?
ACOR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACORDA THERAPEUTICS INC stock?
7 analysts have analysed ACOR and the average price target is 10.2 USD. This implies a price increase of 1443.12% is expected in the next year compared to the current price of 0.661. Check the ACORDA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACORDA THERAPEUTICS INC worth?
ACORDA THERAPEUTICS INC (ACOR) has a market capitalization of 821.03K USD. This makes ACOR a Nano Cap stock.
How many employees does ACORDA THERAPEUTICS INC have?
ACORDA THERAPEUTICS INC (ACOR) currently has 111 employees.
Should I buy ACORDA THERAPEUTICS INC (ACOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACOR, evaluating the profitability, health, valuation and growth aspects
- ACORDA THERAPEUTICS INC (ACOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACORDA THERAPEUTICS INC (ACOR) Sales and EPS estimates to see what analysts future expectations are.
- ACORDA THERAPEUTICS INC (ACOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACORDA THERAPEUTICS INC (ACOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACORDA THERAPEUTICS INC (ACOR) Stock Chart to make your own analysis
- ACORDA THERAPEUTICS INC (ACOR) Latest news and press-releases to stay up to date.
Does ACORDA THERAPEUTICS INC (ACOR) stock pay dividends?
ACOR does not pay a dividend.
When does ACORDA THERAPEUTICS INC (ACOR) report earnings?
ACORDA THERAPEUTICS INC (ACOR) will report earnings on 2024-05-02, after the market close.
What is the Price/Earnings (PE) ratio of ACORDA THERAPEUTICS INC (ACOR)?
ACORDA THERAPEUTICS INC (ACOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-204.57).
ACOR Technical Analysis
ACOR Financial Highlights
Over the last trailing twelve months ACOR reported a non-GAAP Earnings per Share(EPS) of -204.57. The EPS decreased by -129.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACOR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ACOR. The Buy consensus is the average rating of analysts ratings from 7 analysts.